Navigation Links
Celladon Corporation Announces MYDICAR® Enzyme Replacement Therapy for Advanced Heart Failure Provides Sustained Reduction in Clinical Events in Patients for 18 Months Compared with Placebo
Date:5/23/2011

SEATTLE, Wash., May 23, 2011 /PRNewswire/ -- Celladon Corp., a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, today announced that 18-month data from its Phase 2 CUPID clinical trial of MYDICAR® demonstrated continued improvements in clinical outcomes in advanced heart failure patients treated with the genetically-targeted enzyme replacement therapy.

"We are pleased to present data from the long-term follow-up portion of the CUPID trial with MYDICAR demonstrating reduced hospitalizations and other cardiovascular events at 18 months after treatment," said Krisztina Zsebo, Ph.D., CEO and President of Celladon, who presented the study's long-term follow-up results during the American Society of Cell and Gene Therapy 2011.

The study of 39 patients met its primary safety and efficacy endpoints at 6 months for high dose MYDICAR versus placebo.  Additionally, after 12 months of receiving a single infusion of MYDICAR, patients treated with the highest dose versus placebo had an 88 percent risk reduction (Hazard Ratio = 0.12, P=0.003), of major cardiovascular events such as:

  • Death
  • Need for left ventricular assist device (LVAD) or cardiac transplant
  • Episodes of worsening of heart failure

Additionally, the 18-month CUPID data from long-term follow-up demonstrate a durable benefit in preventing major cardiovascular events.

The 12 month data presented in 2010 showed that heart failure, which is a progressive disease, became stabilized in high dose MYDICAR-treated patients: heart failure symptoms, exercise tolerance, serum biomarkers and cardiac function essentially improved or remained stable while these parameters deteriorated substantially in patients treated with placebo and concurrent optimal drug and device therapy.

We believe the efficacy sustained in patients over a 18-mon
'/>"/>

SOURCE Celladon Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Celladon Provides MYDICAR(R) Program Update of First-In-Human Trial for Advanced Heart Failure at American Society of Gene Therapy Annual Meeting
2. Celladon Corporation Announces Presentation of First-in-Human Gene Transfer to Treat Heart Failure at the 12th Annual Meeting of the American Society of Gene Therapy
3. Celladon Announces Presentation of Clinical Data From First-in-Human MYDICAR(R) Trial for Advanced Heart Failure at American Heart Association Scientific Sessions
4. Gumz to Retire as President and CEO of Olympus Corporation of the Americas
5. Medication Delivery Innovator Baxa Corporation Offers Best Practices for Administering Over-the-Counter Liquid Medicine to Babies and Toddlers
6. Families of Spinal Muscular Atrophy Announces Repligen Corporation Receives FDA Approval to Begin Phase I Clinical Trial in SMA
7. TechPrecision Corporation Receives $1.6 Million in New Orders from Existing Customers
8. SenSage Named Cerner Corporations Accelerate Partner of the Year
9. Boston Scientific Announces Favorable Jury Verdict Against Cordis Corporation in Stent Patent Litigation
10. Henry Schein Ranks #317 in 2011 Fortune 500 Ranking of Americas Largest Corporations
11. Omeros Corporation Reports First Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... Calif. , Nov. 21, 2014 In ... and Performance Scrubs carried out a new product development ... industry,s very first "limited edition" lab coat , ... female professors of surgery in the world. The new ... its unisex predecessors, with a sleek envelope collar, vertical ...
(Date:11/21/2014)... Nov. 21, 2014  Heated dialogue in recent months ... from cancer treatments to Gilead,s new hepatitis C drug ... the world questioning what it means to put a ... And while drug pricing is one of ... from both a general business and ethical standpoint – ...
(Date:11/21/2014)... 2014 Clementia Pharmaceuticals, ... dass die Europäische Arzneimittel-Agentur (European Medicines ... Orphan-Medizinprodukt an Palovarotene vergeben hat, den ... von Fibrodysplasia ossificans progressiva (FOP). FOP ... Krankheit, die von schmerzhaften, wiederkehrenden Episoden ...
Breaking Medicine Technology:Medelita Introduces Medical Industry's First Limited Edition Women's Designer Lab Coat 2"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 2"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 3"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 4"The Price of Global Health" Tackles Worldwide Drug-Pricing Debate 5Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 2Clementia Pharmaceuticals erhält EMA-Kennzeichnung als Orphan-Medizin für Palovarotene zur Behandlung von Fibrodysplasia ossificans progressiva 3
(Date:11/21/2014)... Angeles, CA (PRWEB) November 21, 2014 ... reference for the dental practice. It includes everything needed ... . , Procedure Coding with CDT , CDT 2015 ... provided from January 1, 2014 - December 31, 2014. ... report procedures and services on dental claims. There are ...
(Date:11/21/2014)... Even with years of experience under his belt, ... for growth, participating in two recent events for his State ... a networking event with the leaders of State Farm and ... latest and greatest in insurance news and products for his ... team (Stacy, Anthony, Reina and Jacob) as exhibitors at the ...
(Date:11/21/2014)... (PRWEB) November 21, 2014 CARE Surrogacy ... its intended parents — and at the same time enhancing ... sense of optimism for future parents across the globe, the ... , Prospective parents today are zoning in on the skyrocketing ... the encumbering costs, are individuals over-stressing clinical success rates ...
(Date:11/21/2014)... 21, 2014 According to a National ... June 11th, 2014, the inflating system found in certain ... airbag inflates. The force of inflation may cause the ... metal shards may pierce the airbag’s fabric and potentially ... , According to a Bloomberg Business Week article ...
(Date:11/21/2014)... 2014 Nature’s Sleep is excited to announce the ... contest calls for the creation of any type of art — ... encompasses sleep, a bed or a mattress. , “We had ... Vice President of Marketing for Nature’s Sleep, “that we decided to ... than 10,000 creative entries from some very talented artists all the ...
Breaking Medicine News(10 mins):Health News:PMIC Announces CDT PLUS! 2015, the Ultimate Coding Reference for Dentists and Oral Surgeons 2Health News:Kirk Martin Insurance Agency Goes Local and National with State Farm 2Health News:CARE Surrogacy Center Reports on its Multiple Measures of Success 2Health News:CARE Surrogacy Center Reports on its Multiple Measures of Success 3Health News:Takata Airbag Recall Class Action Lawsuit Resource Released by Florida Injury Attorney 2Health News:Takata Airbag Recall Class Action Lawsuit Resource Released by Florida Injury Attorney 3Health News:Nature’s Sleep Kicks Off their 2nd Art Of Sleep Contest 2
... The chances of suffering a stroke are linked to the ... system, a new study from Karolinska Institutet shows. The researchers ... mobilise the body,s own defence against arteriosclerosis and stroke. ... Frostegrd, has previously demonstrated that high levels of a certain ...
... taking action, study finds , FRIDAY, Feb. 12 ... opening in Canada Friday seem more on the ball ... activity enables elite athletes to see and react to ... new study finds. , Researchers analyzed the reaction time ...
... successfully inserted to reopen clogged coronary artery , THURSDAY, ... was said to be "in good spirits" Thursday evening ... two stents inserted into a clogged heart artery. , ... 2004, had been complaining of chest pains. , "Today ...
... , ... in Twin Cities , ... February 12, 2010 -- Ecumen an innovative non-profit senior housing, services and ... on its second senior housing community in Apple Valley and will manage The Seasons at ...
... ... to an underage passenger hurt in a vehicle crash after he left a party. ... Providence, RI (PRWEB) February 12, ... the liability homeowners face when they allow underage drinking in their homes., , ,Details of ...
... , ... Qigong has been called the secret of youth and longevity, and in his latest book, ... Eastern movements can slow the ageing process down and promote youthful skin from the inside ... (PRWEB) February 12, ...
Cached Medicine News:Health News:Ex-President Clinton Said To Be Fine After Heart Procedure 2Health News:Ex-President Clinton Said To Be Fine After Heart Procedure 3Health News:Ecumen Building Senior Housing in Apple Valley, Minnesota and Will Manage New Maplewood, Minnesota Property 2Health News:Ecumen Building Senior Housing in Apple Valley, Minnesota and Will Manage New Maplewood, Minnesota Property 3Health News:Rhode Island Settlement Reflects Homeowner Liability for Serving Alcohol to Those Under 21, Says Providence Lawyer Mark Gemma 2Health News:New Book Reveals How Qigong Could Be The Eastern Answer To Botox 2
... designed with the safety and comfort of the ... (also called SF-6) leaded glass, the industry standard ... as set for optical clarity, visible light transmission, ... is protecting your eyes, it also helps you ...
Panoramic styling that contours closely to the face and brow. Saddle bridge fits average to fuller noses. Adjustable temple hinge adjusts up or down, longer or shorter. Soft cushion behind ear for co...
Qualcraft™ Radiation Protection Eyewear, Metal, Bifocal. Provides maximum comfort and eye protection! Plano (nonprescription). Black with bronze temple bar....
QualCraft™ Radiation-Reducing Eyewear is 50% lighter than other protective eyewear. Manufactured for the ultimate combination of comfort, function, and protection....
Medicine Products: